567 related articles for article (PubMed ID: 23864105)
1. An in silico exploration of the interaction mechanism of pyrazolo[1,5-a]pyrimidine type CDK2 inhibitors.
Li Y; Gao W; Li F; Wang J; Zhang J; Yang Y; Zhang S; Yang L
Mol Biosyst; 2013 Sep; 9(9):2266-81. PubMed ID: 23864105
[TBL] [Abstract][Full Text] [Related]
2. Development of in silico models for pyrazoles and pyrimidine derivatives as cyclin-dependent kinase 2 inhibitors.
Wang F; Ma Z; Li Y; Zhu S; Xiao Z; Zhang H; Wang Y
J Mol Graph Model; 2011 Sep; 30():67-81. PubMed ID: 21763166
[TBL] [Abstract][Full Text] [Related]
3. Molecular simulation studies on the binding selectivity of 2-anilino-4-(thiazol-5-yl)-pyrimidines in complexes with CDK2 and CDK7.
Chohan TA; Qian HY; Pan YL; Chen JZ
Mol Biosyst; 2016 Jan; 12(1):145-61. PubMed ID: 26565382
[TBL] [Abstract][Full Text] [Related]
4. Molecular modeling studies to characterize N-phenylpyrimidin-2-amine selectivity for CDK2 and CDK4 through 3D-QSAR and molecular dynamics simulations.
Chohan TA; Chen JJ; Qian HY; Pan YL; Chen JZ
Mol Biosyst; 2016 Apr; 12(4):1250-68. PubMed ID: 26883408
[TBL] [Abstract][Full Text] [Related]
5. Versatile templates for the development of novel kinase inhibitors: Discovery of novel CDK inhibitors.
Dwyer MP; Paruch K; Alvarez C; Doll RJ; Keertikar K; Duca J; Fischmann TO; Hruza A; Madison V; Lees E; Parry D; Seghezzi W; Sgambellone N; Shanahan F; Wiswell D; Guzi TJ
Bioorg Med Chem Lett; 2007 Nov; 17(22):6216-9. PubMed ID: 17904366
[TBL] [Abstract][Full Text] [Related]
6. Molecular Modeling and Design Studies of Purine Derivatives as Novel CDK2 Inhibitors.
Zhang G; Ren Y
Molecules; 2018 Nov; 23(11):. PubMed ID: 30423939
[TBL] [Abstract][Full Text] [Related]
7. 3D-QSAR and docking studies on pyrazolo[4,3-h]qinazoline-3-carboxamides as cyclin-dependent kinase 2 (CDK2) inhibitors.
Lan P; Chen WN; Xiao GK; Sun PH; Chen WM
Bioorg Med Chem Lett; 2010 Nov; 20(22):6764-72. PubMed ID: 20869873
[TBL] [Abstract][Full Text] [Related]
8. Molecular modelling on small molecular CDK2 inhibitors: an integrated approach using a combination of molecular docking, 3D-QSAR and pharmacophore modelling.
Yuan H; Liu H; Tai W; Wang F; Zhang Y; Yao S; Ran T; Lu S; Ke Z; Xiong X; Xu J; Chen Y; Lu T
SAR QSAR Environ Res; 2013 Oct; 24(10):795-817. PubMed ID: 23941641
[TBL] [Abstract][Full Text] [Related]
9. Inhibition mechanism exploration of quinoline derivatives as PDE10A inhibitors by in silico analysis.
Wu Q; Gao Q; Guo H; Li D; Wang J; Gao W; Han C; Li Y; Yang L
Mol Biosyst; 2013 Mar; 9(3):386-97. PubMed ID: 23354020
[TBL] [Abstract][Full Text] [Related]
10. Interaction mechanism exploration of HEA derivatives as BACE1 inhibitors by in silico analysis.
Wu Q; Li X; Gao Q; Wang J; Li Y; Yang L
Mol Biosyst; 2016 Apr; 12(4):1151-65. PubMed ID: 26915506
[TBL] [Abstract][Full Text] [Related]
11. Structural features of falcipain-3 inhibitors: an in silico study.
Wang J; Li F; Li Y; Yang Y; Zhang S; Yang L
Mol Biosyst; 2013 Sep; 9(9):2296-310. PubMed ID: 23765034
[TBL] [Abstract][Full Text] [Related]
12. Discovery of New Pyrazolopyridine, Furopyridine, and Pyridine Derivatives as CDK2 Inhibitors: Design, Synthesis, Docking Studies, and Anti-Proliferative Activity.
Abdel-Rahman AA; Shaban AKF; Nassar IF; El-Kady DS; Ismail NSM; Mahmoud SF; Awad HM; El-Sayed WA
Molecules; 2021 Jun; 26(13):. PubMed ID: 34206976
[TBL] [Abstract][Full Text] [Related]
13. Synthesis, anticancer evaluation, and molecular docking studies of some novel 4,6-disubstituted pyrazolo[3,4-d]pyrimidines as cyclin-dependent kinase 2 (CDK2) inhibitors.
Cherukupalli S; Chandrasekaran B; Kryštof V; Aleti RR; Sayyad N; Merugu SR; Kushwaha ND; Karpoormath R
Bioorg Chem; 2018 Sep; 79():46-59. PubMed ID: 29753773
[TBL] [Abstract][Full Text] [Related]
14. Novel Pyrazolo[3,4-d]pyrimidines as Potential Cytotoxic Agents: Design, Synthesis, Molecular Docking and CDK2 Inhibition.
Maher M; Kassab AE; Zaher AF; Mahmoud Z
Anticancer Agents Med Chem; 2019; 19(11):1368-1381. PubMed ID: 31038080
[TBL] [Abstract][Full Text] [Related]
15. Molecular docking/dynamics studies of Aurora A kinase inhibitors.
Talele TT; McLaughlin ML
J Mol Graph Model; 2008 Jun; 26(8):1213-22. PubMed ID: 18096419
[TBL] [Abstract][Full Text] [Related]
16. Exploring the selectivity of a ligand complex with CDK2/CDK1: a molecular dynamics simulation approach.
Tripathi SK; Singh SK; Singh P; Chellaperumal P; Reddy KK; Selvaraj C
J Mol Recognit; 2012 Oct; 25(10):504-12. PubMed ID: 22996593
[TBL] [Abstract][Full Text] [Related]
17. Theoretical study on the interaction of pyrrolopyrimidine derivatives as LIMK2 inhibitors: insight into structure-based inhibitor design.
Shen M; Zhou S; Li Y; Li D; Hou T
Mol Biosyst; 2013 Oct; 9(10):2435-46. PubMed ID: 23881296
[TBL] [Abstract][Full Text] [Related]
18. Exploring the structure determinants of pyrazinone derivatives as PDE5 3HC8 inhibitors: an in silico analysis.
Li Y; Wu W; Ren H; Wang J; Zhang S; Li G; Yang L
J Mol Graph Model; 2012 Sep; 38():112-22. PubMed ID: 23085160
[TBL] [Abstract][Full Text] [Related]
19. Decoding molecular mechanism of inhibitor bindings to CDK2 using molecular dynamics simulations and binding free energy calculations.
Chen J; Pang L; Wang W; Wang L; Zhang JZH; Zhu T
J Biomol Struct Dyn; 2020 Mar; 38(4):985-996. PubMed ID: 30843759
[TBL] [Abstract][Full Text] [Related]
20. Synthesis of a new series of pyrazolo[1,5-a]pyrimidines as CDK2 inhibitors and anti-leukemia.
Almehmadi SJ; Alsaedi AMR; Harras MF; Farghaly TA
Bioorg Chem; 2021 Dec; 117():105431. PubMed ID: 34688130
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
